Effectiveness of vitamin D therapy in improving metabolomic biomarkers in obesity phenotypes: Two randomized clinical trials.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

To address the existing gap, their study sought to compare changes in metabolomic profiles of obesity phenotypes (metabolically healthy obese (MHO) and metabolically unhealthy obese (MUHO)) patients with sub-optimal levels of vitamin D following vitamin D supplementation.

Why It Was Studied

Uncertainty remains about the effect of vitamin D therapy on biomarkers of health status in obesity.

The molecular basis underlying this controversy is largely unknown.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

The researchers conducted two randomized double-blind clinical trials on participants with either of the two obesity phenotypes from Tehran province.

These phenotypes were determined by the Adult Treatment Panel-III criteria.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Pre- and post-supplementation plasma metabolomic profiling were performed using Liquid chromatography coupled to a triple quadrupole mass spectrometry.

Multivariable linear regression was used to explore the association of change in each metabolite with the trial assignment (vitamin D/placebo) across obesity phenotypes.

What Was Measured

PubMed files the paper under topics including Biomarkers, Body Mass Index, Insulin Resistance, Metabolome, Obesity, Obesity, Metabolically Benign and Phenotype.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (International journal of obesity (2005)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.